CareDx, Inc. (NASDAQ:CDNA - Get Free Report) Director Richard Bryan Riggsbee sold 5,285 shares of CareDx stock in a transaction on Monday, November 16th. The stock was sold at an average price of $74.77, for a total transaction of $395,159.45. Following the sale, the director owned 34,027 shares of the company's stock, valued at $2,544,198.79. The trade was a 13.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
CareDx Stock Performance
NASDAQ CDNA traded down $0.12 on Wednesday, reaching $74.44. 537,257 shares of the company's stock traded hands, compared to its average volume of 1,298,944. The stock has a 50 day moving average price of $67.77 and a 200-day moving average price of $37.51. The firm has a market cap of $3.91 billion, a price-to-earnings ratio of 112.97 and a beta of 2.51. CareDx, Inc. has a fifty-two week low of $15.56 and a fifty-two week high of $90.87.
CareDx (NASDAQ:CDNA - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.45. The business had revenue of $139.36 million during the quarter, compared to analysts' expectations of $121.96 million. CareDx had a return on equity of 9.74% and a net margin of 25.86%. The company's revenue for the quarter was up 39.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.03 EPS. As a group, equities research analysts anticipate that CareDx, Inc. will post 1.00 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on CDNA. Zacks Research raised shares of CareDx from a "hold" rating to a "strong-buy" rating in a research note on Thursday, November 5th. Piper Sandler initiated coverage on shares of CareDx in a report on Wednesday, November 11th. They set an "overweight" rating and a $100.00 price target on the stock. Craig Hallum upgraded shares of CareDx from a "hold" rating to a "buy" rating and set a $64.00 price objective for the company in a research report on Monday, August 3rd. HC Wainwright reissued a "neutral" rating and set a $46.00 target price on shares of CareDx in a research note on Friday, July 31st. Finally, BTIG Research increased their target price on shares of CareDx from $81.00 to $92.00 and gave the stock a "buy" rating in a research note on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $70.33.
View Our Latest Report on CareDx
Institutional Investors Weigh In On CareDx
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Algert Global LLC acquired a new stake in shares of CareDx in the third quarter valued at about $975,000. Allworth Financial LP boosted its position in CareDx by 12.9% during the third quarter. Allworth Financial LP now owns 2,870 shares of the company's stock worth $187,000 after acquiring an additional 327 shares during the last quarter. C M Bidwell & Associates Ltd. purchased a new stake in CareDx during the 3rd quarter valued at about $92,000. Aquatic Capital Management LLC grew its stake in CareDx by 37.0% during the 3rd quarter. Aquatic Capital Management LLC now owns 9,421 shares of the company's stock valued at $612,000 after acquiring an additional 2,546 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in CareDx by 33.1% in the 3rd quarter. Goldman Sachs Group Inc. now owns 931,678 shares of the company's stock valued at $60,559,000 after acquiring an additional 231,685 shares during the last quarter.
CareDx Company Profile
(
Get Free Report)
CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.